Drug Type Monoclonal antibody |
Synonyms CS 1003, CS-1003, CS1003 + [1] |
Target |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Nofazinlimab | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Hepatocellular Carcinoma | Phase 3 | US | 13 Dec 2019 | |
Advanced Hepatocellular Carcinoma | Phase 3 | CN | 13 Dec 2019 | |
Advanced Hepatocellular Carcinoma | Phase 3 | IT | 13 Dec 2019 | |
Advanced Hepatocellular Carcinoma | Phase 3 | PL | 13 Dec 2019 | |
Advanced Hepatocellular Carcinoma | Phase 3 | ES | 13 Dec 2019 | |
Advanced Hepatocellular Carcinoma | Phase 3 | TW | 13 Dec 2019 | |
Liver Cancer | Phase 3 | - | - | |
Lymphoma | Phase 1 | CN | 29 Oct 2018 | |
Advanced cancer | Phase 1 | AU | 09 May 2018 | |
Advanced Malignant Solid Neoplasm | Phase 1 | AU | 09 May 2018 |
NCT03809767 (ASCO2022) Manual | Phase 1 | Unresectable Hepatocellular Carcinoma First line | 20 | Lenvatinib+CS1003 | xwebctojmi(yfylbekabj) = Confirmed ORR was changed from 30.0% to 45.0% (95% CI: 23.06%, 68.47%) with 9 pts achieving partial response. xzuaubwcih (nwgqnlphqt ) View more | Positive | 02 Jun 2022 |
Phase 1 | 36 | vudgneoerr(genxzrzzfo) = 5 (9.3%) pts had AEs leading to discontinuation of CS1002 and CS1003. xlffxhjtwd (qhwxcwetxy ) View more | Positive | 09 Dec 2021 | |||
NCT03809767 (ESMO2020) Manual | Phase 1 | Unresectable Hepatocellular Carcinoma First line | 19 | fguaxazctp(ywxpwcopxe) = zzbmgipjak ctuxazrbmp (gtrwahheqp ) View more | Positive | 17 Sep 2020 |